Investors are noticing ripe opportunity in Cytokinetics, a late-stage biopharma company targeting medicines for specialty heart diseases, that has seen shares skyrocket in recent months.
Shares of Cytokinetics have jumped about 69% over the past three months and are up 31% year to date.…